By Fineline Cube 
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and East China Normal University (ECNU) announced a strategic partnership to advance AI-driven drug discovery, marking a significant milestone for ECNU’s School of Pharmacy in building dedicated AI drug research facilities and talent pipelines.
Partnership Overview
| Item | Detail |
|---|---|
| Companies | Zhejiang Hisun Pharmaceutical (600267.SH), East China Normal University |
| Focus Area | AI + Drug R&D collaboration |
| Strategic Objective | Accelerate AI-driven drug discovery, joint laboratory construction, technology breakthroughs, and talent cultivation |
| Previous ECNU AI Labs | Joint labs for AI-driven small nucleic acid drugs, AI intelligent manufacturing, AI drug exploration |
Collaboration Areas
① AI Drug Research & Development: Utilizing artificial intelligence to accelerate discovery and design of new medications, addressing critical bottlenecks in traditional R&D.
② Joint Laboratory Construction: Building dedicated facilities to support collaborative research initiatives, including high‑throughput screening and computational biology platforms.
③ Key Technology Breakthroughs: Conducting joint research to overcome technical challenges in target identification, lead optimization, and ADMET prediction.
④ Talent Cultivation: Developing specialized professionals equipped for AI + pharmaceutical industry integration, creating a pipeline of 50‑100 AI drug scientists by 2028.
Market Context & Strategic Significance
China AI Drug Discovery Market: ¥4.5 billion (2025), projected ¥18 billion by 2030 (32% CAGR).
Academic‑Industry Model: ECNU’s AI expertise combined with Hisun’s clinical development and manufacturing scale creates a competitive moat in AI drug translation.
Financial Impact: Hisun expects ¥200‑300 million in R&D cost savings and 15‑20% faster development timelines within 3 years.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the partnership’s research outcomes, talent development, and market impact. Actual results may differ materially due to R&D challenges, regulatory hurdles, and competitive dynamics in AI drug discovery.-Fineline Info & Tech